Monoclonal Antibody Denosumab Can Delay Onset Of Bone Metastases In Prostate Cancer Patients
9/25/2011
Denosumab inhibits RANKL, a protein involved in bone metabolism, and appears to delay bone metastases onset in patients with prostate cancer, researchers from the Georges Pompidou Hospital, Paris, France, reported at the European Multidisciplinary Cancer Congress 2011, Stockholm, Sweden. The scientists say theirs is the first large-scale human study to show such an effect from denosumab (Xgeva)...
Post-menopausal breast cancer patients who receive zoledronic acid in addition to chemotherapy have a significantly lower risk of cancer recurrence, researchers from Weston Park Hospital, Sheffield, England, reported at the European Multidisciplinary Cancer Congress 2011, Stockholm, Sweden...
Bone-Strengthening Drug Gives Pain Relief In Prostate Cancer Bone Metastases
9/25/2011
Many prostate cancer patients develop bone metastases, and controlling the pain these cause can be difficult. Now the first large randomised Phase III trial of a bisphosphonate drug in these patients has shown that a single dose of the drug is as good for pain relief as single dose radiotherapy, the standard treatment for bone metastases...
Synchronous Chemoradiation Lowers Risk Of Breast Cancer Coming Back
9/25/2011
Synchronous chemoradiation - administering radiotherapy during or in between chemotherapy cycles to females with early breast cancer significantly reduces the chances of the cancer returning, researchers from Birmingham, England, explained at the European Multidisciplinary Cancer Congress 2011...
Head And Neck Cancer Patients Have Range Of Unmet Needs
9/25/2011
Patients with head and neck cancer say they have a range of unmet needs from pre-diagnosis through the post-treatment period, researchers reported at the 2011 European Multidisciplinary Cancer Congress (EMCC)...
Trastuzumab Emtansine Keeps Types Of Breast Cancer In Check
9/25/2011
Today, results from the trial of a new investigational medication, trastuzumab emtansine a targeted antibody drug conjugate (known as ADC), have shown that the drug considerably increases the time that advanced HER2-positive breast cancer is kept in check while reducing adverse effects...
Rise In Prostate Biopsy Complications And High Post-Procedure Hospitalization Rate
9/25/2011
In a study of complication rates following prostate biopsy among Medicare beneficiaries, Johns Hopkins researchers have found a significant rise in serious complications requiring hospitalization. The researchers found that this common outpatient procedure, used to diagnose prostate cancer, was associated with a 6.9 percent rate of hospitalization within 30 days of biopsy compared to a 2...
Gene Number And Protein Expression Revealed Simultaneously By Novel Technique
9/25/2011
Researchers have discovered a method for simultaneously visualizing gene number and protein expression in individual cells...
Breast Cancer Cells Destroyed In Laboratory By Virus
9/25/2011
A nondisease-causing virus kills human breast cancer cells in the laboratory, creating opportunities for potential new cancer therapies, according to Penn State College of Medicine researchers who tested the virus on three different breast cancer types that represent the multiple stages of breast cancer development...
Automatic Speech Recognition Error Rate In Breast Imaging Reports
9/25/2011
Breast imaging reports generated using an automatic speech recognition system are nearly six times more likely to contain major errors than those generated with conventional dictation transcription, a new study in Canada shows...